Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic dermatitis (AD).
STAT6 drives the inflammatory response in the blood and skin, and KT-621 works by reducing the levels of STAT6 in the blood and skin.
The phase 1b BroADen trial included 22 people with moderate to severe AD over 28 days, with a 14-day follow-up period.
In the trial, KT-621 reduced the levels of STAT6 in the blood and skin significantly, and this reduction remained consistent. At day 29, the average reduction of STAT6 in the blood was 98%, and for skin lesions – an area with high levels of STAT6 – the average reduction of STAT6 was 94%.
In addition, at day 29, the Eczema Area and Severity Index (EASI) score was reduced by 63% for all patients. Various type 2 biomarkers associated with inflammatory response were also found to have been reduced.
The safety and tolerability profiles of KT-621 were favourable, with no serious adverse events being reported.
Nello Mainolfi, founder, president and CEO of Kymera, said: “The BroADen study results exceeded our highest expectations and provide a powerful additional validation of our industry-leading STAT6 degrader programme.
“KT-621 demonstrated its potential to deliver a first-in-class, once-a-day oral treatment for type 2 inflammatory diseases across every measure we evaluated, including STAT6 degradation, biomarker modulation, clinical activity, impact on other comorbid type 2 diseases and safety.”
Atopic dermatitis is a chronic skin condition characterised by itchy, inflamed and discoloured skin. As well as causing physical discomfort and pain, it can lead to embarrassment and social isolation.